Description:

The current trial sought to study the safety and efficacy of alirocumab, a PCSK9 inhibitor, compared with placebo in heterozygous familial hypercholesterolemia (HeFH) patients who were on maximal tolerated doses of a statin, but had low-density lipoprotein cholesterol (LDL-C) levels ≥160 mg/dl.

Not a Member?

As a member of the ACC, you'll get full access to all articles, clinical research, and more!